Business Wire

GSMA Launches Inclusive Tech Lab

24.9.2019 11:00:00 EEST | Business Wire | Press release

Share

The GSMA today announced the launch of the GSMA Inclusive Tech Lab, which will take a hands-on approach to research, testing and development of the inclusive technologies of the future. The Bill and Melinda Gates Foundation has provided three years of funding for the GSMA Inclusive Tech Lab, and will sit on the Advisory Group alongside industry representatives including GoPay, IDEMIA, KaiOS, Mowali, Telenor, the University of Washington, VEON and Vodafone.

“In launching the GSMA Inclusive Tech Lab, we are taking a bold new step to support and stimulate innovation through greater experimentation and a willingness to take risks,” said John Giusti, Chief Regulatory Officer, GSMA. “The GSMA Mobile for Development programme has already had a direct impact on improving the lives of 58 million people. The Lab will allow our team of dedicated ‘technopreneurs’ the opportunity to take a hands-on approach to break down the barriers to economic and social inclusion further.”

“We are proud to be collaborating with the GSMA and funding the Inclusive Tech Lab to strategize, build and pilot technologies to support the industry with innovations to drive financial inclusion for the poorest,” said Matt Bohan, Senior Programme Officer, Financial Services for the Poor at The Bill and Melinda Gates Foundation. “The Lab will enable us to create and explore products, from interoperability platforms to standardised APIs and more, that will help the industry to drive innovation to include poor people at a whole new pace and scale.”

The Lab will work on a range of areas that drive inclusion. These will comprise expanding the openness and interoperability of payment systems, service accessibility for women and vulnerable populations, and digital identities for unregistered people, as well as other topics of relevance. The GSMA, together with industry stakeholders, will establish and share proofs of concept aimed at increasing financial and digital inclusion for underserved groups.

The services of the Lab will be three-fold; research, innovation projects and technological assets (e.g. web-based test environments). The Lab will benefit from guidance received from leading industry figures making up its global Advisory Group, who will help to assess, prioritise, shape and contribute towards potential project ideas received by the Lab. Following direction from the Advisory Group, projects deemed feasible will be further researched and developed. The Lab will build readily usable products and insights up to proof-of-concept (and potentially support an initial commercial launch, as appropriate). Critically, the Lab will ensure learnings and Lab-developed solutions will be available to the broader industry, with the first results available to the industry in the first quarter of 2020.

Giusti concluded, “Today there are challenges of expanding access to financial services, bridging the digital services gap for women and vulnerable user groups, and providing digital identity solutions for the one billion individuals with no form of ID. These challenges drive our activity as we work on the transformative digital innovations of tomorrow.”

To find out more about the GSMA Inclusive Tech Lab, and how you can contribute, please go to the following link: www.gsma.com/lab

-ENDS-

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.

For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Gearóid Cashman
+44 79 7679 0169

GCashman@webershandwick.com
GSMA Press Office
pressoffice@gsma.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye